Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 12, 2019 (7 years ago)

Azacitidine 125 Mg / 5 Ml Sub-Q Syringe

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

AZACITIDINE 125 MG / 5 ML SUB-Q SYRINGE; AZACITIDINE 75 MG (3 ML) SYRINGE, AZACITIDINE 135 MG / 5.4 ML SUB-Q SYRINGE, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233

Drug: Azacitidine

Recalling firm
Infusion Options, Inc.
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1751-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Azacitidine recalls

See all
Class III · Low risk

Azacitidine

Failed stability specifications

Terminated Stability / shelf life Dr. Reddy's Laboratories, Inc. NDC 43598-465-62 D-0576-2022
Class III · Low risk

Azacitidine

Failed stability specifications

Terminated Stability / shelf life Dr. Reddy's Laboratories, Inc. NDC 43598-305-62 D-0575-2022

Other recalls by Infusion Options, Inc.

All 2019 recalls